Status:
COMPLETED
A Study to Describe a Group of Spanish Patients With FMF and to Identify Suboptimally Treated Patients With Minimal Disease Activity and Its Impact on Quality of Life
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Familial Mediterranean Fever
Eligibility:
All Genders
Up to 28 years
Brief Summary
A retrospective, non-interventional, single-center study conducted in Spain, based on the collection of data from the medical histories of patients with Familial Mediterranean fever (FMF) diagnosed du...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients with FMF clinically and/or genetically diagnosed during childhood according to the site's clinical practice.
- Patients with at least 3 months of follow-up from the date of diagnosis, at the time of their enrollment in the study.
- Exclusion criteria:
- Patients with autoinflammatory disease excluding FMF.
- Patients with recurrent fever of another etiology (infectious, tumor or other).
Exclusion
Key Trial Info
Start Date :
March 30 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 28 2024
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT06923124
Start Date
March 30 2023
End Date
May 28 2024
Last Update
April 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
East Hanover, New Jersey, United States, 07936